NCT05587439 (INHERIT) is a clinical trial of Data and Specimen Collection in Lung Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT05587439?

NCT05587439 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT05587439?

Interventions in NCT05587439: Data and Specimen Collection.

What condition does NCT05587439 study?

NCT05587439 studies Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases.

Is NCT05587439 still recruiting?

NCT05587439 is currently recruiting now. Last updated 10 July 2025.

Last reviewed 2025-07-10 · How we verify

NCT05587439: INHERIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating Hereditary Risk In Thoracic Cancers (INHERIT)

Recruiting now Last updated 10 July 2025

What this trial tests

trial testing Data and Specimen Collection in Lung Cancer in 500 participants. Currently enrolling.

Timeline

1 January 2023

Primary endpoint
1 November 2027

1 November 2027

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 January 2023
Primary completion	1 November 2027
Estimated completion	1 November 2027
Sites	2 locations across United States

Drugs / interventions tested

Data and Specimen Collection

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Genetic Disease — all drugs for Genetic Disease →
Genetic Predisposition — all drugs for Genetic Predisposition →
Hereditary Diseases — all drugs for Hereditary Diseases →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Lung Cancer or Genetic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to learn more about the inherited risk for developing lung cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Lung cancer in patients who have never smoked - an emerging disease.
LoPiccolo J, Gusev A, Christiani DC, Jänne PA. · · 2024 · cited 197× · PMID 38195910 · DOI 10.1038/s41571-023-00844-0
Young lung cancer: from diagnosis to survivorship.
Florez N, Kiel L, Kaufman R, LoPiccolo J, et al · · 2025 · PMID 40641929 · DOI 10.3389/fonc.2025.1570143

Verify or expand the search:

Other trials of Data and Specimen Collection

Trials testing the same drug.

NCT05265429 — Biology of Young Lung Cancer Study: The YOUNG LUNG Study · recruiting
NCT04541654 — Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress · recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05587439 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 10 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05587439.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing